An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

Détails

Ressource 1Télécharger: BIB_3CD56A6881FB.P001.pdf (6633.37 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_3CD56A6881FB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Périodique
Journal of Experimental Medicine
Auteur⸱e⸱s
Harari A., Bart P. A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., Burnet S., Cellerai C., Erlwein O., Barber T., Moog C., Liljestrom P., Wagner R., Wolf H., Kraehenbuhl J. P., Esteban M., Heeney J., Frachette M. J., Tartaglia J., McCormack S., Babiker A., Weber J., Pantaleo G.
ISSN
1540-9538
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
205
Numéro
1
Pages
63-77
Langue
anglais
Résumé
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, followed by NYVAC C at weeks 20 and 24. The primary immunogenicity endpoints were measured at weeks 26 and 28 by the quantification of T cell responses using the interferon gamma enzyme-linked immunospot assay. Our results indicate that the DNA C plus NYVAC C vaccine regimen was highly immunogenic, as indicated by the detection of T cell responses in 90% of vaccinees and was superior to responses induced by NYVAC C alone (33% of responders). The vaccine-induced T cell responses were (a) vigorous in the case of the env response (mean 480 spot-forming units/10(6) mononuclear cells at weeks 26/28), (b) polyfunctional for both CD4 and CD8 T cell responses, (c) broad (the average number of epitopes was 4.2 per responder), and (d) durable (T cell responses were present in 70% of vaccinees at week 72). The vaccine-induced T cell responses were strongest and most frequently directed against Env (91% of vaccines), but smaller responses against Gag-Pol-Nef were also observed in 48% of vaccinees. These results support the development of the poxvirus platform in the HIV vaccine field and the further clinical development of the DNA C plus NYVAC C vaccine regimen
Mots-clé
AIDS Vaccines , Animals , CD4-Positive T-Lymphocytes , CD8-Positive T-Lymphocytes , chemistry , Codon , Dna , env Gene Products,Human Immunodeficiency Virus , Enzyme-Linked Immunosorbent Assay , Epitope Mapping , Epitopes , gag Gene Products,Human Immunodeficiency Virus , genetics , Hiv-1 , Humans , immunology , Interferon-gamma , metabolism , methods , nef Gene Products,Human Immunodeficiency Virus , Peptides , Phenotype , Switzerland , therapeutic use , Vaccines , Viral Vaccines
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/01/2009 22:14
Dernière modification de la notice
20/08/2019 13:33
Données d'usage